Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 6
Submit an article Journal homepage
2,197
Views
9
CrossRef citations to date
0
Altmetric
Letters to the Editor

Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy

Alexis Genthona Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1293-4236
ORCID Icon,
Thibault Chiarabinib Service de Maladies Infectieuses et Tropicales, Saint-Antoine Hospital, Paris, France
,
Pierre Baylacb Service de Maladies Infectieuses et Tropicales, Saint-Antoine Hospital, Paris, France
,
Nadia Valinb Service de Maladies Infectieuses et Tropicales, Saint-Antoine Hospital, Paris, France
,
Tomas Urbinac Médecine Intensive Réanimation, Hôpital Saint-Antoine, Assistance Publique – Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris Cedex 12, France
,
Jérome Pacanowskib Service de Maladies Infectieuses et Tropicales, Saint-Antoine Hospital, Paris, France
,
Arsène Mekiniand AP-HP, Hôpital Saint Antoine, service de médecine interne et Inflammation (DHU i2B), Faculté de Médecine Sorbonne Université, Paris, France, Paris, France
,
Eolia Brissota Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France
,
Fella M.’Hammedi-Bouzinaa Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France
,
Simona Lapusana Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France
,
Mohamad Mohtya Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France
,
Karine Lacombee Sorbonne Université, Inserm U1136, Hôpital Saint-Antoine, AP-HP, Paris, France
&
Patrick Ingilizb Service de Maladies Infectieuses et Tropicales, Saint-Antoine Hospital, Paris, France
 show all
Pages 1502-1505 | Received 09 Nov 2020, Accepted 22 Dec 2020, Published online: 08 Jan 2021

References

  • Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054–1062.
  • Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13.
  • Somers EC, Eschenauer GA, Troost JP, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020. DOI:https://doi.org/10.1093/cid/ciaa954
  • Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–e484.
  • Alijotas-Reig J, Esteve-Valverde E, Belizna C, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review. Autoimmun Rev. 2020;19(7):102569.
  • Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040–4047.
  • Laurence J, Mulvey JJ, Seshadri M, et al. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol. 2020;219:108555.
  • Giudice V, Pagliano P, Vatrella A, et al. Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study. Front Pharmacol. 2020;11:857.
  • Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33(17–18):1389–1401.
  • Chan JF-W, Yao Y, Yeung M-L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904–1913.
  • de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875–4884.
  • Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383:517–525.
  • Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio. 2018;9(5):e01753-18.
  • Jiang Y, Zhao G, Song N, et al. Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4 -transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018;7(1):1–12.
  • Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–474.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.